Scottish Ministers are legally required to consult, develop and implement fisheries management measures for inshore Marine Protected Areas and Priority Marine Features.

Developing the evidence-base for effective fisheries management measures, and undertaking statutory requirements, for more than 160 sites and areas within the inshore region is a complicated and challenging process. We are continuing to work at pace to complete the necessary statutory social, economic and environmental assessments ahead of launching a public consultation.

Fisheries management measure will be implemented as soon as possible following analysis of the consultation responses and a final decision on the measures has been taken.

Maternity services continue to be provided for women in Wigtownshire, including local antenatal and postnatal care, scanning and the option of midwife-supported home birth for women who choose to birth locally. Women who require more complex maternity care continue to be supported by the full clinical team at Dumfries and Galloway Royal Infirmary. Responsibility for the design and delivery of local services lies with NHS Boards and Integration Joint Boards in line with their duties to deliver safe, effective and sustainable care. The findings and rationale behind the IJB’s decision not to reopen the birth unit in Stranraer are publicly available on the Dumfries and Galloway Health and Social Care Partnership’s website: Integration Joint Board Meetings 2021-2025 – Dumfries & Galloway Health & Social Care. Like all Boards, NHS Dumfries and Galloway is expected to continually assess risk and outcomes as part of routine clinical governance.

The Scottish Government does not hold this information.

Restorative Justice services can be offered by a wide range of organisations - not only by local authorities - including by third sector or faith-based organisations.

We continue to work in partnership with Community Justice Scotland and the Children and Young People’s Centre for Justice focussing on achieving our vision – to have restorative justice available at a time that is appropriate to the people and case involved; consistent; evidence-led, trauma informed and of a high standard.

The regulations for the licensing, safety and efficacy of medicines are reserved to the UK Government and are the responsibility of the Medicines and Healthcare products Regulatory Agency (MHRA). For a medicine to be routinely prescribed in the UK, it firstly needs to receive a marketing authorisation. This process ensures the safety, quality and efficacy of medicines placed on the market in the UK. It is the responsibility of individual pharmaceutical companies to apply to the MHRA for a marketing authorisation.

Tovorafenib does not currently have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). It is the responsibility of individual pharmaceutical companies to apply to the MHRA for a marketing authorisation. If a marketing authorisation is granted, the Scottish Medicines Consortium (SMC) would welcome a submission for tovorafenib, however the decision on whether to submit a medicine for appraisal to the SMC, and the timing of that submission, is entirely for the pharmaceutical company that holds the marketing authorisation for the medicine to make.

NHS Dumfries and Galloway has confirmed that all pregnant women in Wigtownshire continue to receive all of the maternity care that they require. Antenatal and postnatal maternity care, including maternity scanning is delivered by midwives locally via the Oaktree Family Centre in Stranraer. Women can also choose a home birth and will be supported by local midwives. Women who require more complex care may require some of their antenatal and postnatal care at Dumfries and Galloway Royal Infirmary and will be advised to birth there.

We recognise that being physically active is one of the very best things we can do for our physical, social and mental health and we want to ensure that everyone has the opportunity to be active, regardless of their circumstances.

Our Physical Activity For Health Framework, published in October 2024, describes our evidence-based approach to achieving our vision of a Scotland where more people are more active, more often. Participation in walking sport is one way in which people can be more active and we recognise the important role of Walking Football Scotland in providing walking football opportunities across Scotland.

The Scottish Government’s 2021-22 Programme for Government included a commitment to progress work to tackle violence against men and boys, investing in services which support male survivors of rape and domestic abuse.

In line with our PfG commitment we have invested in services which support male survivors of abuse by funding the following organisations:

• Men’s Advice Line, who provide emotional support and practical advice and information for male victims of domestic abuse in Scotland.
• SACRO’s FearFree Project which supports male and LGBTI survivors of domestic violence.
• AMIS, a charity that support men experiencing domestic abuse through their national helpline, website and training services.
• The Scottish Domestic Abuse and Forced Marriage Helpline to support both male and female victims and survivors.
• ASSIST, who as part of their work provide advocacy support to male survivors of domestic abuse in the West of Scotland and the Lothians.
• LGBT Domestic Abuse project, which works across Scotland to raise awareness and improve service responses of LGBT people's experiences of domestic abuse and other forms of gender based violence.

All legislative changes adopted to address domestic abuse and rape and sexual assault, such as the Domestic Abuse (Scotland) Act 2018 similarly protect both female and male victims.

Furthermore, Equally Safe, Scotland’s strategy to prevent and eradicate all forms of violence against women and girls, recognises that men and boys can also be victims of violence and abuse. Its focus on the disproportionate harm women and girls face due to this type of violence is in line with United Nations and World Health Organisation approaches, and enables us to meet our obligations under international human rights legislation such as CEDAW and the Istanbul Convention.

The provision of patient record systems remains the operational responsibility of Health Boards, but at a national level I can confirm it is our intention to launch the first version of a personalised digital health and social care service from December 2025. This was set out in the answer to question S6W-30875 on 11 November 2024.

The Scottish Government emphasises that this provides citizens with access to their own health and care data and accordingly will address the desire across Scotland for individuals to have access to a single shared patient record.

It is important to recognise that implementation of the service for our workforce, will build on our current Clinical Portal system, which currently enables many Health Boards across Scotland to have access to health information as part of the integrated record. This commitment is also set out in our recently published Programme for Government 2025-26 -https://www.gov.scot/binaries/content/documents/govscot/publications/advice-and-guidance/2025/05/programme-government-2025-26/documents/programme-government-2025-26/programme-government-2025-26/govscot%3Adocument/programme-government-2025-26.pdf.

We highly recognise the importance of ensuring staff have access to the correct patient information where required, and we continue to improve this through development of our National Digital Platform, which enables the storage and integration of data for digital services that are public facing. We have also applied our learning collated from the use of the Clinical Portals, and we will continue to collate and apply intelligence gathered to our ongoing development of Integrated Records.

All answers to written Parliamentary Questions are available on the Parliament’s website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

Tovorafenib does not currently have a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). Before a company can place a medicine on the market in the UK it has to obtain regulatory approval by submitting data demonstrating the quality, safety and efficacy of the medicine in terms of treating a specified condition. This data is derived from clinical trials. If a marketing authorisation is granted, the Scottish Medicines Consortium (SMC) would welcome a submission for tovorafenib. The Scottish Government is aware that there is an international, phase 3 clinical trial looking at tovorafenib for the first line treatment of paediatric low-grade glioma which is open to people who meet the eligibility criteria. It is the responsibility of the clinician in charge of a patient’s care to advise on what treatment options may be available.